PR Newswire PROVIDENCE, R.I., Dec. 8, 2025 PROVIDENCE, R.I., Dec. 8, 2025 /PRNewswire/ -- EpiVax, Inc., with U.S. Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist collaborators, announces the publication of a study titled "Immunogenicity Risk Assessment of ...
Read MorePR Newswire WASHINGTON, Dec. 9, 2025 Speakers explore how we can better protect the heroes who protect us all. WASHINGTON, Dec. 9, 2025 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—hosted a Patient Advocacy Summit on the unique ...
Read MorePR Newswire SAN DIEGO, Dec. 9, 2025 SAN DIEGO, Dec. 9, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that they will present their Phase 1/2 study results of spevatamig ...
Read MorePR Newswire HONG KONG, Dec. 9, 2025 HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with SOX regimen ...
Read MorePR Newswire FLORENCE, Italy and NEW YORK, Dec. 8, 2025 FLORENCE, Italy and NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the ...
Read MorePR Newswire ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Dec. 9, 2025 FDA grants a Type A meeting on December 18th to review new and expanded datasets submitted by Saol to help identify a feasible path forward without the need for an additional clinical trial ROSWELL, Ga. and DUBLIN ...
Read MorePR Newswire LONDON, Dec. 8, 2025 Ready-to-use sepsis therapy marks new advancement in time-critical treatment LONDON, Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces the launch of the first-of-its-kind, ...
Read MorePR Newswire CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Dec. 8, 2025 Consistent and robust efficacy demonstrated across bleed types, locations, and dose cohorts The weekly dosing cohort achieved an estimated 87% reduction in annualized treated bleeding rate (ATBR) Results validate ...
Read MorePR Newswire LAS VEGAS, Dec. 9, 2025 The amyotrophic lateral sclerosis market is expected to grow owing to the increasing prevalence of the disease, along with the promising emerging pipeline therapies, such as Masitinib (AB Sciences), PrimeC (Neurosense Therapeutics), RNS60 (Revalesio), ...
Read MorePR Newswire SACRAMENTO, Calif., Dec. 9, 2025 Evolve Releases Landmark White Paper on California's Home Modification Outcomes — Delivering a New Blueprint for Lower Healthcare Costs, Better Patient Outcomes, and Stronger Health Plan Performance SACRAMENTO, Calif., Dec. 9, 2025 ...
Read MorePR Newswire NEW YORK, Dec. 9, 2025 Study Findings May Provide Key Insight into Parkinson's Disease NEW YORK, Dec. 9, 2025 /PRNewswire/ -- The brain-chemical surge that comes with running may bolster coordination and speed in the old and young alike, a new study of middle-aged mice ...
Read MorePR Newswire STOCKHOLM, Dec. 9, 2025 STOCKHOLM, Dec. 9, 2025 /PRNewswire/ -- As the world's first country to be prescribed for its health benefits, Sweden is now shining a light on one of its most awe-inducing wellness experiences. Aurora Borealis – the original arctic light therapy. The ...
Read MorePR Newswire PHILADELPHIA, Dec. 9, 2025 PHILADELPHIA, Dec. 9, 2025 /PRNewswire/ -- As the festive season approaches and Americans prepare for weeks of holiday parties, colder weather and gift-shopping marathons, new research from TENA, the global leader in incontinence care, reveals the ...
Read MorePR Newswire GOTHENBURG, Sweden, Dec. 8, 2025 GOTHENBURG, Sweden, Dec. 8, 2025 /PRNewswire/ -- Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced ...
Read MorePR Newswire YONGIN, South Korea, Dec. 9, 2025 YONGIN, South Korea, Dec. 9, 2025 /PRNewswire/ -- GC Genome, a leading clinical genomics and liquid biopsy company, announced that its study analyzing cell-free DNA (cfDNA) fragmentation patterns in 1,154 healthy individuals has been published ...
Read More
MEDINDIA
English
हिन्दी
Español
français
中文